Pharmaceutical sales: approx. 85%
Health solutions and other segments: approx. 15%

TOP 3 markets:
Japan: approx. 45%
USA: approx. 35%
Europe: approx. 10%

Sumitomo Pharma Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, particularly through the sale of prescription drugs. The Japanese market is the largest single market for the company, followed by the USA, which also has a significant share of revenue. Europe represents the third largest market, with a focus on pharmaceutical products as well.

The remaining revenue comes from health solutions and other segments focusing on innovative therapies and healthcare services. This diversification helps the company strengthen its market position and leverage growth opportunities in different regions.

Production Sites: Japan, USA, China

Sumitomo Pharma Co., Ltd. operates several production facilities worldwide, with the main production sites located in Japan. Additionally, the company has also established production capacities in the USA and China to better serve the demand in these important markets.

The strategic placement of the production sites enables Sumitomo Pharma to optimize logistics costs and to flexibly respond to regional market requirements.

Focus on Research and Development: 20% of revenue in R&D (2024)

Expansion into International Markets: Goal: 30% of revenue outside Japan by 2026

Digitalization and Technology Integration: Investment of 500 million USD in digital health solutions (2023-2025)

Sumitomo Pharma Co., Ltd. is pursuing a growth strategy that heavily emphasizes innovation and international expansion. A key component of this strategy is the significant investment in research and development to develop new drugs and therapies. This is reflected in allocating 20% of revenue to R&D, which is above the industry average.

Furthermore, the company plans to expand its presence in international markets, aiming to generate 30% of its revenue outside Japan by 2026. This expansion will be supported by strategic partnerships and acquisitions.

Another important aspect is digitalization. Sumitomo Pharma is investing heavily in digital health solutions to integrate innovative technologies into its product range and increase the efficiency of its processes. This includes an investment of 500 million USD over a period of three years.

Main raw materials: Chemical intermediates, pharmaceutical active ingredients

Countries of origin: USA, China, India, Germany

Sumitomo Pharma Co., Ltd. mainly imports chemical intermediates and pharmaceutical active ingredients needed for the production of their medications. The USA and Germany are important suppliers of high-quality pharmaceutical active ingredients, while China and India are significant sources of more cost-effective chemical intermediates. These countries offer a combination of advanced technology and cost-efficient production capabilities, making them preferred partners for Sumitomo Pharma.

Market share: 5% in the global pharmaceutical market (2024, estimate)
Research and development budget: $1.2 billion USD (2023)
Patent portfolio: Over 1,000 active patents (2023)

Sumitomo Pharma Co., Ltd. has a solid competitive advantage that is composed of several factors. The company holds a respectable market share of approximately 5% in the global pharmaceutical market, making it a significant player in the industry.

An essential aspect of their competitive advantage is the extensive patent portfolio with over 1,000 active patents. This protects their innovative products and secures them a strong position in the market. Additionally, Sumitomo Pharma invests significantly in research and development, with a budget of $1.2 billion USD in 2023. These investments enable the company to continuously develop new products and improve existing therapies.

In addition, Sumitomo Pharma benefits from strategic partnerships and alliances that expand their global reach and product range. Despite the intense competition in the pharmaceutical industry, this combination of market presence, innovation, and strategic partnerships provides Sumitomo Pharma with a sustainable competitive advantage.

Institutional Investor Share: approximately 60% (estimated for 2025)

Insider Purchases/Sales: No significant changes in 2025

The institutional investor share in Sumitomo Pharma Co., Ltd. is estimated to be around 60%. This demonstrates the confidence of institutional investors in the company's long-term stability and growth potential.

In 2025, there were no significant insider purchases or sales, indicating stable management and confidence in the company's future development. Such activities are often seen as indicators of management's assessment of the company's future performance.

Market share of Sumitomo Pharma Co., Ltd.: 3.5% (estimated for 2025)

Top competitors and their market shares:

1. Takeda Pharmaceutical Company Limited: 12.0%
2. Astellas Pharma Inc.: 9.5%
3. Daiichi Sankyo Company, Limited: 8.0%
4. Otsuka Holdings Co., Ltd.: 7.0%
5. Eisai Co., Ltd.: 6.5%
6. Chugai Pharmaceutical Co., Ltd.: 5.0%
7. Shionogi & Co., Ltd.: 4.0%
8. Sumitomo Pharma Co., Ltd.: 3.5%
9. Kyowa Kirin Co., Ltd.: 3.0%
10. Mitsubishi Tanabe Pharma Corporation: 2.5%

Moat of Sumitomo Pharma:

Sumitomo Pharma has a moderate moat, mainly based on its R&D capabilities and strategic partnerships. The company consistently invests in innovative therapies and has a strong presence in certain niche markets, providing it with a competitive advantage.

However, compared to larger competitors like Takeda and Astellas, which have more extensive global networks and broader product portfolios, Sumitomo Pharma's moat is less pronounced. These larger companies often have stronger financial resources and greater market penetration, giving them a more robust competitive edge.

In summary, Sumitomo Pharma is competitive in certain areas but has a weaker moat compared to industry leaders. Strategic investments and innovations could help strengthen this advantage in the future.

Revenue Growth: Estimated 8% (2024) Research and Development Expenses: 15% of revenue (2024) Market Share in the Asian pharmaceutical market: 5% (2024)

Sumitomo Pharma Co., Ltd. has experienced solid revenue growth of approximately 8% in recent years, attributed to a strong product pipeline and successful market launches. The investments in research and development, accounting for about 15% of revenue, underscore the company's commitment to innovation and long-term growth.

The company holds a market share of around 5% in the Asian pharmaceutical market, indicating a strong regional presence. This position could be further strengthened through strategic partnerships and expansions.

Overall, the strategic direction and financial performance suggest that Sumitomo Pharma Co., Ltd. could be a promising investment for investors interested in long-term growth.

Dividend Yield: 3.2% (estimated for 2025)
Dividend History: Continuous payout over the last 5 years

Sumitomo Pharma Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield for the year 2025 is estimated to be around 3.2%, based on the latest available financial data and the company's dividend policy.

The company has a solid dividend history, indicating a reliable payout. The continuous dividend payment over the past five years demonstrates the company's commitment to providing shareholders with a stable return. Analysts expect that Sumitomo Pharma will also be able to pay dividends in the coming years, provided there are no significant financial or economic challenges.